Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses

April 12, 2022 1:12 pm

by Alison Kanski

NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more

Elimusertib Shows Promise for Solid Tumors With ATM Loss and DDR Gene Defects

April 10, 2022 2:29 pm

by Ariana Pelosci

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Patients with advanced solid tumors who have ATM gene alterations

Read more

New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy

April 5, 2022 3:27 pm

by Charles Bankhead

— Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk

The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis … Read more

Key to detecting ovarian cancer early may be in the fallopian tubes

April 4, 2022 3:20 pm

by Caren Begun

Tennis legend Chris Evert—known for her 18-time grand slam success in the sport—has made recent headlines after revealing an early-stage ovarian cancer diagnosis and speaking out to help others by sharing her personal experience.

According to the … Read more

BRCA Testing Underused in Women With Ovarian Cancer

January 14, 2022 9:00 am

by M. Alexander Otto, MMS, PA

Despite unequivocal recommendations for universal germline BRCA testing in women with ovarian cancer, an analysis of a large commercial insurance database between 2008 and 2018 found that only about one third (33.9%) of such … Read more

Study Shows How Ovarian Cancer Starts in High-Risk Women

December 28, 2021 10:47 am

by Cedars-Sinai

Findings Hold Potential for Predicting Many Years in Advance Which Women With the BRCA-1 Mutation Will Develop Disease

Newswise — Los Angeles (December 28, 2021). –Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S., … Read more

Repare Therapeutics’ RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology

November 4, 2021 11:09 am

by Alison Kanski

NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.

Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more

Women with genetic mutations fare no worse with breast or ovarian cancer, study finds

October 1, 2021 12:00 am

By Krista Conger

Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.

Women newly diagnosed with breast or ovarian cancer who are also … Read more

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumor cells

August 13, 2021 9:27 pm

A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more

Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors

June 18, 2021 12:21 pm

Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more

Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer

June 8, 2021 11:28 am

by Victoria Forster, PhD

Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1Read more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

March 20, 2021 4:00 pm

Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.

By Charles Bankhead

A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.

Treatment with rucaparib (Rubraca) … Read more

How Biomarker Testing May Help Women Battling Ovarian Cancer

February 18, 2021 6:00 pm

Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.

By

Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of

Read more

Proton Therapy Induces Biologic Response to Attack Treatment-Resistant Cancers

February 17, 2021 4:00 pm

Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in … Read more

Common Genetic Test Often Wrong When Identifying Rare Disease-Causing Variants Such as BRCA1 and BRCA2, Study Says

February 16, 2021 10:00 am

By Sandee LaMotte, CNN

A genetic test used to detect common traits many people share is not reliable in identifying rare disease-causing variations, such as those that can predict breast and ovarian cancer, a new study has found.

The SNP … Read more

Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer

October 10, 2020 5:00 pm

By Savannah Demko

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

“Preclinical studies suggest the potential for synergy between … Read more

Bayer’s ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest

September 29, 2020 4:00 pm

Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.

The … Read more

Why Some Cancers May Respond Poorly to Key Drugs Discovered

September 22, 2020 4:00 pm

Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University … Read more

Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

September 18, 2020 3:00 pm

Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more